Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) FCF Margin (2024 - 2025)

Silence Therapeutics' FCF Margin history spans 2 years, with the latest figure at 50797.06% for Q4 2025.

  • For Q4 2025, FCF Margin fell 5068821.0% year-over-year to 50797.06%; the TTM value through Dec 2025 reached 11149.55%, down 1099270.0%, while the annual FY2025 figure was 11149.55%, 1099270.0% down from the prior year.
  • FCF Margin for Q4 2025 was 50797.06% at Silence Therapeutics, down from 8722.4% in the prior quarter.
  • Across five years, FCF Margin topped out at 58.24% in Q1 2024 and bottomed at 50797.06% in Q4 2025.